Pharmac to fund another brand of ADHD medication (opens original article in a new tab)

Pharmac will fund the Rubifen LA brand of methylphenidate from October to improve supply and treatment options for ADHD patients, following ongoing global supply issues.

• Pharmac will fund Rubifen LA, a long-acting methylphenidate, from October to address supply issues.
• Rubifen LA offers the same strengths as Ritalin LA plus a 60mg option, aiming to improve treatment access for ADHD patients.
• Global supply challenges and demand have impacted methylphenidate availability since 2023, with pressures expected until 2026.